Anthera commences Phase 2 study of IgA nephropathy therapy
Scheduled to enroll a minimum of 48 patients from Asia Pacific geographies, the multicenter, placebo-controlled, double-blind study will randomize the subjects into one active treatment arm or one
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.